MedTrace Logo

ABC294640 in Treating Patients With Advanced Solid Tumors

NCT01488513 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-01-07

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Please note that the FDA OOPD is participating as a funding source.

Conditions

Interventions

DRUG

sphingosine kinase-2 inhibitor ABC294640

Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID

Sponsors & Collaborators

  • Apogee Biotechnology Corporation

    collaborator INDUSTRY

  • Medical University of South Carolina

    collaborator OTHER

  • FDA Office of Orphan Products Development

    collaborator FED

  • National Cancer Institute (NCI)

    collaborator NIH

  • RedHill Biopharma Limited

    lead INDUSTRY

Principal Investigators

  • Carolyn Britten, MD · Medical University of South Carolina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-08-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01488513 on ClinicalTrials.gov